CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Thomas J. DesRosier, Esq. to the position of executive vice president, chief legal and administration officer, and secretary. Mr. DesRosier will be responsible for global legal operations, information technology and other administrative functions. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D.
Mr. DesRosier has more than 30 years of global biotechnology and pharmaceutical industry experience and joins ARIAD from Cubist Pharmaceuticals, Inc., where he held the same position as the one he will assume at ARIAD. Prior to Cubist, Mr. DesRosier was senior vice president, general counsel, North America of Sanofi, a position he assumed following the acquisition of Genzyme Corporation by Sanofi in 2011, where he had served as Genzyme’s senior vice president, chief legal officer.
“Mr. DesRosier is a talented and experienced attorney, who has had a stellar career in the pharmaceutical and biotechnology industries,” stated Dr. Berger. “We are excited to welcome Tom to ARIAD, and I look forward to working closely with him as we make the transition to a profitable oncology company over the next three years. I expect Tom to have a positive impact on the Company in many areas immediately upon joining our leadership team.”
Prior to his 12-year tenure at Genzyme, Mr. DesRosier held a number of senior legal positions at Wyeth Pharmaceuticals, Genetics Institute, and E.I. DuPont de Nemours. He received his J.D. from Wake Forest University School of Law and his B.A. degree in Chemistry from the University of Vermont.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
This press release contains “forward-looking statements” which are based on management's good-faith expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to our ability to execute on our corporate strategies for profitability; our ability to successfully commercialize and generate profits from sales of our products; competition from alternative therapies, our reliance on the performance of third-party manufacturers and specialty pharmacies for the distribution of Iclusig; preclinical data and early-stage clinical data that may not be replicated in later-stage clinical studies, the costs associated with our research, development, manufacturing and other activities, the enrollment, conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. After the date of this document, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results or to changes in the Company's expectations, except as required by law.